A primary treatment strategy for type 2 diabetes relies upon improving insulin sensitivity, such as with the thiazolidinedione-class drug rosiglitazone (RG), a powerful insulin sensitizer. The gene discussed is INS; the disease is type 2 diabetes mellitus.